SCHEMBL8250585

SCHEMBL8250585

O=C(O)/C=C/c1ccc(-c2ccc(CO)cc2)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC2 Q92769 3/20 0.70
▸ HDAC8 Q9BY41 2/20 0.56
▸ HCAR2 Q8TDS4 2/20 0.55
▸ CA12 O43570 1/20 0.55
▸ AKR1B10 O60218 1/20 0.55
▸ CA1 P00915 1/20 0.55
▸ CA2 P00918 1/20 0.55
▸ ESR1 P03372 1/20 0.55
▸ CA3 P07451 1/20 0.55
▸ PKM P14618 1/20 0.55
▸ TYR P14679 1/20 0.55
▸ AKR1B1 P15121 1/20 0.55
▸ CA4 P22748 1/20 0.55
▸ CA6 P23280 1/20 0.55
▸ DPP4 P27487 1/20 0.55
▸ CA5A P35218 1/20 0.55
▸ CA7 P43166 1/20 0.55
▸ CA9 Q16790 1/20 0.55
▸ ESR2 Q92731 1/20 0.55
▸ CA14 Q9ULX7 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3292958 1.00 HDAC2 (0.70) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL2300815 0.94 HCAR2 (0.61) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL2300813 0.94 HCAR2 (0.61) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL4946176 0.86 HCAR2 (0.71) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL4946181 0.86 HCAR2 (0.71) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL1481590 0.84 F3 (0.56) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL1481587 0.84 F3 (0.56) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL23512479 0.84 KDM4E (0.57) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL7957010 0.84 KDM4E (0.57) HDAC2HDAC8HCAR2CA12AKR1B10
SCHEMBL7957004 0.84 KDM4E (0.57) HDAC2HDAC8HCAR2CA12AKR1B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728039-B2 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-06-01 — — US disclosed
US-7728039-B2 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2010-06-01 — — US disclosed
US-20080319082-A1 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-12-25 — — US disclosed
US-20080319082-A1 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2008-12-25 — — US disclosed
WO-2007000383-A1 BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) 2007-01-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080319082-A1 Biphenyl and Naphthyl-Phenyl Hydroxamic Acid Derivatives VHL, ARNT, AHR HDAC2 220/4885HDAC8 101/4885HCAR2 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback